Article Text
Paper
A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease
Statistics from Altmetric.com
This is a PDF-only article. The first page of the PDF of this article appears above.
Supplementary materials
Conflict of interest: J-FC, PR and SJvD have served as consultants to PDL BioPharma, Inc. DWH is supported by a grant from the Netherlands Organisation for Health Research and Development, and has received honoraria and funding for research. MC, HD, TP, MT, and LZ are employees of PDL BioPharma, Inc. None declared by the other authors.